ARUP Newsroom

The American College of Medical Genetics and Genomics (ACMG) recommends whole exome and whole genome sequencing (WES/WGS) be considered as a first- or second-tier test for patients with congenital anomalies (CAs), developmental delay (DD), or intellectual disability (ID).

Come to booth #1038 to see ARUP’s showcase of various suites of neurology laboratory testing and meet ARUP medical directors and experts ready to answer questions.

Dan Albertson, MD, will serve as president of the University Business Unit.

Michael Pyne, MS, a scientist in ARUP’s R&D Infectious Disease group, performs next generation sequencing (NGS) testing for HIV drug resistance, which is a lab-developed test. 

An expert in TAR DNA-binding protein of 43 kDa (TDP-43), neuropathologist Qinwen Mao, MD, PhD, subspecialty director of Neuropathology at ARUP, is working to identify biomarkers that predict the presence of TDP-43 pathology to contribute to the diagnosis of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease.